Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
This is the first major brand refresh of CanSinoBIO since its inception in 2009
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
The business is a recognized leader in managing Covid-19 and mRNA research programs
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Subscribe To Our Newsletter & Stay Updated
